Skip to search formSkip to main contentSkip to account menu

deferasirox

Known as: deferasirox [Chemical/Ingredient], 4-(3,5-bis-(2-hydroxyphenyl)-(1,2,4)-triazol-1-yl)benzoic acid, 4-(3,5-Bis-(hydroxy-phenyl)-1,2,4-triazol-1-yl)-benzoic Acid 
A drug used to treat too much iron in the blood caused by blood transfusions. It is being studied in the treatment of myelodysplastic syndromes (a… 
National Institutes of Health

Related topics

Related topics

9 relations

Broader (3)

BenzoatesIron Chelating AgentsTriazoles

Narrower (2)

ExjadeICL 670
Iron Chelating Activity [MoA]deferasirox 125 MG Tablet for Oral Suspension [Exjade]deferasirox 360 MG Oral Tablet [Jadenu]deferasirox Oral Tablet

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Iron chelation monotherapy in transfusion-dependent beta-thalassemia major patients: a comparative study of deferasirox and deferoxamine
Introduction Iron overload is the primary cause of mortality and morbidity in thalassemia major (TM) despite advances in… 
2012
2012
Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle‐cell disease
What is known and Objective:  Patients with sickle‐cell disease (SCD) receiving chronic transfusions of red blood cells are at… 
2010
2010
In vitro time-kill activities of ciprofloxacin alone and in combination with the iron chelator deferasirox against Vibrio vulnificus
Iron plays a major role in the growth and virulence of ferrophilic organisms like Vibrio vulnificus. People who reside in the… 
2010
2010
Synthesis and antiproliferating activity of iron chelators of hydroxyamino-1,3,5-triazine family.
2010
2010
Chelation of aluminum by combining deferasirox and deferiprone in rats
The hypothesis that two known chelators deferasirox and deferiprone (L1) might be more efficient as combined treatment than as… 
2009
2009
Myelodysplasia paranoia: iron as the new radon.
Review
2009
Review
2009
Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy.
Patients with myelodysplastic syndromes (MDS) often require chronic RBC transfusions, which can lead to iron overload. Without… 
2008
2008
Effect of Deferasirox (Exjade ® ) on Labile Plasma Iron Levels in Heavily Iron-Overloaded Patients with Transfusion-Dependent Anemias Enrolled in the Large-Scale, Prospective 1-Year EPIC Trial
Background: Labile plasma iron (LPI) is a toxic, directly chelatable form of non-transferrin- bound iron that is produced… 
Review
2007
Review
2007
Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes.
2005
2005
Iron Chelation Efficiency of Deferasirox (Exjade®, ICL670) in Patients with Transfusional Hemosiderosis.
Iron excretion can be calculated according to Angelucci et al (NEJM 2000). As applied to the novel oral iron chelator deferasirox… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)